• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by uniQure N.V.

    2/13/24 4:33:59 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QURE alert in real time by email
    SC 13G 1 p24-0810sc13g.htm UNIQURE N.V.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

     

    uniQure N.V.

    (Name of Issuer)
     

    Ordinary shares, par value €0.05 per share

    (Title of Class of Securities)
     

    N90064101

    (CUSIP Number)
     

    December 31, 2023

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. N9006410113GPage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Vestal Point Capital, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    3,925,000

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    3,925,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,925,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.2%

    12

    TYPE OF REPORTING PERSON

    IA, PN

             

     

    CUSIP No. N9006410113GPage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Ryan Wilder

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    3,925,000

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    3,925,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,925,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.2%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. N9006410113GPage 4 of 7 Pages

     

     

    Item 1(a). NAME OF ISSUER:
      The name of the issuer is uniQure N.V.  (the "Company").
       
    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
      The Company's principal executive offices are located at Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands.
       
    Item 2(a). NAME OF PERSON FILING:
      This statement is filed by:
       
      (i) Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the Ordinary Shares (as defined in Item 2(d) below) directly held by the Vestal Point Fund and Account; and
       
      (ii) Mr. Ryan Wilder ("Mr. Wilder"), the  Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the Ordinary Shares directly held by the Vestal Point Fund and Account.
       
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Ordinary Shares reported herein.  
       
    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
      The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012.
       
    Item 2(c). CITIZENSHIP:
      The Investment Manager is a Delaware limited partnership.  Mr. Wilder is a citizen of the United States.
       
    Item 2(d). TITLE OF CLASS OF SECURITIES:
      Ordinary shares, par value €0.05 per share (the "Ordinary Shares").
       

     

    CUSIP No. N9006410113GPage 5 of 7 Pages

     

    Item 2(e). CUSIP NUMBER:
      N90064101
       
    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g) x Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                             

       
    Item 4. OWNERSHIP:
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
       
      The percentages set forth herein are calculated based upon 47,811,479 Ordinary Shares outstanding as of November 15, 2023, as reported in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on November 17, 2023.
       

     

    CUSIP No. N9006410113GPage 6 of 7 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
      Not applicable.
       
    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
      See Item 2(a).  The Vestal Point Fund and Account have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares reported herein.  
       
    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
      Not applicable.
       
    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
      Not applicable.
       
    Item 9. NOTICE OF DISSOLUTION OF GROUP:
      Not applicable.
       
    Item 10. CERTIFICATION:
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. N9006410113GPage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: February 13, 2024

     

     

    VESTAL POINT CAPITAL, LP
    By: VESTAL POINT CAPITAL, LLC, its general partner  
         
    By: /s/ Ryan Wilder  
    Name: Ryan Wilder  
    Title: Chief Investment Officer and Managing Partner  
         
         
    /s/ Ryan Wilder  
    Ryan Wilder  

     

    Get the next $QURE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QURE

    DatePrice TargetRatingAnalyst
    11/4/2025Outperform → Mkt Perform
    William Blair
    8/14/2025$30.00Neutral → Outperform
    Mizuho
    4/1/2025$38.00Buy
    Chardan Capital Markets
    12/10/2024Outperform → Strong Buy
    Raymond James
    10/10/2024$20.00Outperform
    Raymond James
    2/29/2024$8.00Buy → Neutral
    Goldman
    12/19/2023$52.00 → $10.00Buy → Neutral
    Mizuho
    3/17/2022$40.00Neutral → Buy
    UBS
    More analyst ratings

    $QURE
    SEC Filings

    View All

    SEC Form 10-Q filed by uniQure N.V.

    10-Q - uniQure N.V. (0001590560) (Filer)

    11/10/25 7:17:35 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - uniQure N.V. (0001590560) (Filer)

    11/10/25 7:06:08 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by uniQure N.V.

    SCHEDULE 13G - uniQure N.V. (0001590560) (Subject)

    11/5/25 11:49:28 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    uniQURE N.V. Investigation: Investors Encouraged to Contact Kirby McInerney LLP

    The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of uniQURE N.V. ("uniQURE" or the "Company") (NASDAQ:QURE) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On November 3, 2025, uniQure disclosed that the Company "believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide th

    11/11/25 8:00:00 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    ~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington's disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 months and supportive trends across key clinical and biomarker endpoints ~ ~ Preliminary feedback from FDA at a recent pre-Biologics License Application (BLA) meeting for AMT-130 indicated a key shift from prior regulatory communications; uniQure plans to urgently interact with the FDA to define next steps ~ ~ Advanced enrollment of Phase I/IIa study of AMT-260 in mesial temporal lobe epilepsy, with additional clinical data expected in the first half of 2026 ~ ~ Presented initial

    11/10/25 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure to Announce Third Quarter 2025 Financial Results

    LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report third quarter 2025 financial results before market open on Monday, November 10, 2025. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure's website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or

    11/6/25 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gut Robert exercised 15,840 units of Ordinary Shares at a strike of $4.57 and sold $856,881 worth of Ordinary Shares (31,434 units at $27.26), decreasing direct ownership by 28% to 40,145 units (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    11/10/25 4:54:55 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kaye Jack sold $1,177,517 worth of Ordinary Shares (38,810 units at $30.34) and exercised 38,810 units of Ordinary Shares at a strike of $9.88 (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    11/6/25 5:01:40 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO, Managing Director Kapusta Matthew C exercised 226,316 units of Ordinary Shares at a strike of $6.52 and sold $9,382,473 worth of Ordinary Shares (226,316 units at $41.46) (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    9/26/25 7:43:03 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    uniQure downgraded by William Blair

    William Blair downgraded uniQure from Outperform to Mkt Perform

    11/4/25 7:43:29 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure upgraded by Mizuho with a new price target

    Mizuho upgraded uniQure from Neutral to Outperform and set a new price target of $30.00

    8/14/25 8:07:02 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets resumed coverage on uniQure with a new price target

    Chardan Capital Markets resumed coverage of uniQure with a rating of Buy and set a new price target of $38.00

    4/1/25 8:05:22 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Leadership Updates

    Live Leadership Updates

    View All

    uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

    ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O'Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O'Keefe will lead the development and execution of uniQure's global commercialization strategy for AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease. Her responsibilities include all commercial functions and medical affairs. Ms. O'K

    6/11/25 8:00:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

    LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately. He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company's Basel, Switzerland office. Dr. Abi-Saab will be responsible for leading all clinical research and development, regulatory affairs, medical affairs, and program management at uniQure. With Dr. Abi-Saab's appointment, Dr. Ricardo Dolmetsch becomes President and Chief Scientific Officer. He

    6/26/23 7:11:42 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Financials

    Live finance-specific insights

    View All

    uniQure to Announce Third Quarter 2025 Financial Results

    LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report third quarter 2025 financial results before market open on Monday, November 10, 2025. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure's website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or

    11/6/25 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease

    ~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~ ~ High-dose AMT-130 also demonstrated statistically significant slowing of disease progression as measured by TFC, a key secondary endpoint, and favorable trends across additional clinical measures ~ ~ Mean cerebrospinal fluid NfL levels were below baseline at 36 months ~ ~ AMT-130 continued to be generally well-tolerated with a manageable safety profile ~ ~ uniQure plans to submit a BLA in the first quarter of 2026, with anticipated U.S. launch later that year, pending approval ~

    9/24/25 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

    ~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 2025 ~ ~ Presented case study from first participant treated with AMT-260 for refractory mesial temporal lobe epilepsy showing 92% seizure reduction with no serious adverse events through first five months of follow up ~ ~ Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer ~ ~ Cash, cash equivalents and current investment securities of approximately $

    7/29/25 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    11/14/24 12:01:42 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    11/13/24 4:05:14 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    10/25/24 9:48:27 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care